Molecular Endotypes of Chronic Idiopathic Urticaria

Summary

This study plans to learn more about why some people with Chronic Idiopathic Urticaria (CIU) respond to treatment with omalizumab (Xolair). It will test people before they receive treatment with omalizumab as part of standard of care, to see if there are differences in their blood and skin that can predict who responds to treatment.

Timeline

Start

2022-01-01

Primary completion

2025-03

Completion

2025-03

Drugs

Indications